- Home
- EDN vs CERT Comparison
EDN vs CERT Comparison
Compare EDN & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDN | CERT |
|---|---|---|
| Founded | 1992 | 2008 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Retail: Computer Software & Peripheral Equipment |
| Sector | Utilities | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EDN | CERT |
|---|---|---|
| Price | $28.34 | $6.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $12.78 |
| AVG Volume (30 Days) | 123.7K | ★ 2.6M |
| Earning Date | 03-10-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | 0.07 |
| Revenue | ★ $1,678,118,877.00 | $415,551,000.00 |
| Revenue This Year | $32.93 | $10.75 |
| Revenue Next Year | $24.64 | $6.32 |
| P/E Ratio | ★ $17.95 | $97.87 |
| Revenue Growth | 3.69 | ★ 11.47 |
| 52 Week Low | $14.38 | $6.45 |
| 52 Week High | $40.26 | $15.69 |
Technical Indicators
Market Signals| Indicator | EDN | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 45.93 | 19.61 |
| Support Level | $28.06 | $6.45 |
| Resistance Level | $30.39 | $7.29 |
| Average True Range (ATR) | 1.89 | 0.44 |
| MACD | -0.08 | -0.22 |
| Stochastic Oscillator | 31.02 | 4.64 |
Price Performance
Historical ComparisonAbout EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.